795 related articles for article (PubMed ID: 27534444)
1. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.
Shichijo S; Hirata Y; Niikura R; Hayakawa Y; Yamada A; Mochizuki S; Matsuo K; Isomura Y; Seto M; Suzuki N; Suzuki H; Yamamoto S; Sugimoto T; Omae T; Okamoto M; Watabe H; Togo G; Takano N; Fukui K; Ito Y; Koike K
J Dig Dis; 2016 Oct; 17(10):670-675. PubMed ID: 27534444
[TBL] [Abstract][Full Text] [Related]
2. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
Tanabe H; Yoshino K; Ando K; Nomura Y; Ohta K; Satoh K; Ichiishi E; Ishizuka A; Otake T; Kohgo Y; Fujiya M; Okumura T
Ann Clin Microbiol Antimicrob; 2018 Jun; 17(1):29. PubMed ID: 29950163
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
Kiyotoki S; Nishikawa J; Sakaida I
Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237
[TBL] [Abstract][Full Text] [Related]
4. Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
Kusunoki M; Yuki M; Ishitobi H; Kobayashi Y; Nagaoka M; Takahashi Y; Fukuba N; Komazawa Y; Shizuku T; Kinoshita Y
Intern Med; 2019 Jun; 58(11):1549-1555. PubMed ID: 30713328
[TBL] [Abstract][Full Text] [Related]
5. Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy.
Ozaki H; Harada S; Takeuchi T; Kawaguchi S; Takahashi Y; Kojima Y; Ota K; Hongo Y; Ashida K; Sakaguchi M; Tokioka S; Sakamoto H; Furuta T; Tominaga K; Higuchi K
Digestion; 2018; 97(3):212-218. PubMed ID: 29393194
[TBL] [Abstract][Full Text] [Related]
6. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
Sue S; Kuwashima H; Iwata Y; Oka H; Arima I; Fukuchi T; Sanga K; Inokuchi Y; Ishii Y; Kanno M; Terada M; Amano H; Naito M; Iwase S; Okazaki H; Komatsu K; Kokawa A; Kawana I; Morimoto M; Saito T; Kunishi Y; Ikeda A; Takahashi D; Miwa H; Sasaki T; Tamura T; Kondo M; Shibata W; Maeda S
Intern Med; 2017; 56(11):1277-1285. PubMed ID: 28566587
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.
Matsumoto H; Shiotani A; Katsumata R; Fujita M; Nakato R; Murao T; Ishii M; Kamada T; Haruma K; Graham DY
Dig Dis Sci; 2016 Nov; 61(11):3215-3220. PubMed ID: 27659671
[TBL] [Abstract][Full Text] [Related]
8. Comparative study: Vonoprazan and proton pump inhibitors in
Sakurai K; Suda H; Ido Y; Takeichi T; Okuda A; Hasuda K; Hattori M
World J Gastroenterol; 2017 Jan; 23(4):668-675. PubMed ID: 28216974
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication.
Jung YS; Kim EH; Park CH
Aliment Pharmacol Ther; 2017 Jul; 46(2):106-114. PubMed ID: 28497487
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
Sue S; Ogushi M; Arima I; Kuwashima H; Nakao S; Naito M; Komatsu K; Kaneko H; Tamura T; Sasaki T; Kondo M; Shibata W; Maeda S
Helicobacter; 2018 Apr; 23(2):e12456. PubMed ID: 29271026
[TBL] [Abstract][Full Text] [Related]
11. Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line
Maruyama M; Tanaka N; Kubota D; Miyajima M; Kimura T; Tokutake K; Imai R; Fujisawa T; Mori H; Matsuda Y; Wada S; Horiuchi A; Kiyosawa K
Can J Gastroenterol Hepatol; 2017; 2017():4385161. PubMed ID: 28349044
[No Abstract] [Full Text] [Related]
12. Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection.
Shinmura T; Adachi K; Yamaguchi Y; Izawa S; Hijikata Y; Ebi M; Funaki Y; Ogasawara N; Sasaki M; Kasugai K
J Gastrointestin Liver Dis; 2019 Dec; 28(4):389-395. PubMed ID: 31826057
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Tanabe H; Ando K; Sato K; Ito T; Goto M; Sato T; Fujinaga A; Kawamoto T; Utsumi T; Yanagawa N; Ichiishi E; Otake T; Kohgo Y; Nomura Y; Ueno N; Sugano H; Kashima S; Moriichi K; Fujiya M; Okumura T
Dig Dis Sci; 2017 Nov; 62(11):3069-3076. PubMed ID: 28664410
[TBL] [Abstract][Full Text] [Related]
14. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M
Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
Ono S; Kato M; Nakagawa S; Mabe K; Sakamoto N
Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28098408
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Kajihara Y; Shimoyama T; Mizuki I
Scand J Gastroenterol; 2017 Feb; 52(2):238-241. PubMed ID: 27806639
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen.
Shinozaki S; Osawa H; Sakamoto H; Hayashi Y; Kobayashi Y; Miura Y; Lefor AK; Yamamoto H
Kaohsiung J Med Sci; 2018 Aug; 34(8):456-460. PubMed ID: 30041763
[TBL] [Abstract][Full Text] [Related]
18. A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-containing 7-day Triple Therapy against Helicobacter pylori.
Noda H; Noguchi S; Yoshimine T; Goji S; Adachi K; Tamura Y; Izawa S; Ebi M; Yamamoto S; Ogasawara N; Funaki Y; Sasaki M; Kasugai K
J Gastrointestin Liver Dis; 2016 Sep; 25(3):283-8. PubMed ID: 27689190
[TBL] [Abstract][Full Text] [Related]
19. Treatment of
Kanu JE; Soldera J
World J Gastroenterol; 2024 Mar; 30(9):1213-1223. PubMed ID: 38577188
[TBL] [Abstract][Full Text] [Related]
20. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.
Kusano C; Gotoda T; Suzuki S; Ikehara H; Moriyama M
J Gastroenterol; 2018 Jun; 53(6):718-724. PubMed ID: 29110085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
